Trial Profile
A Phase 2a, Randomized, Double-blind, Placebo (Vehicle)-Controlled, Dose Finding Trial to Assess the Safety, Tolerability and Efficacy of NRD135S.E1 in Patients With Neuropathic Pain Associated With Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs NRD135S E1 (Primary)
- Indications Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Novaremed
- 23 Jun 2022 Primary endpoint (Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS) (150 mg/day)) has not been met, according to a Novaremed media release.
- 23 Jun 2022 Primary endpoint ( Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS) (40 mg/day)) has been met, according to a Novaremed media release.
- 23 Jun 2022 Results published in the Media Release